Glycated albumin is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, which is easy to perform. Glycated albumin is considered as a potential tool for the diagnosis of diabetes. This glycated albumin is a better marker of short-term glycemic control than glycated hemoglobin (A1C) test. According to an article published in the National Center for Biotechnology Information (NCBI), 2016, glycated albumin assay is the efficient way to reduce diabetic complications and manage diabetic patients by early diagnosis.
The global glycated albumin assay market was estimated to be valued at US$ 428.1 million in 2019, and is expected to exhibit a CAGR of 7.7% during the forecast period (2019-2027).
Figure 1. Global Glycated Albumin Assay Market Share (%), By Product Type
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities, in order to develop novel diagnostic approach for diabetes and regulatory approval for such assay and tests are expected to be major factors driving growth of the global glycated albumin assay market over the forecast period
Increasing research and development activities for development of albumin assay test is expected to drive market growth over the forecast period. According to the article published in Journal of Laboratory and Precision Medicine in September 2019, glycated albumin appears to have potential as a glycation index in diagnosing and screening diabetes parameters such as evaluating glycemic control status especially for patients with end-stage renal disease (ESRD) and pregnant women as a predictor of diabetic complications
Moreover, increasing launches of digital healthcare platform by key players operating in the market is expected to propel the segment growth. For instance, in November 2016, Epinex Diagnostics, Inc. launched ‘Am I Diabetic’ mobile phone app for iPhone and android devices, on the occasion of National Diabetes Month. The function of this app is to provide educational information and awareness about diabetes.
Rising adoption of inorganic growth strategies such as collaborations by key players, in order to develop and launch innovative glycated albumin assay is expected to drive the market growth. For instance, in July 2018, Ortho Clinical Diagnostics (Ortho) entered into collaboration with Diazyme Laboratories, Inc. to introduce its three new Microtip Partnership Assays (MSA) such as Glycated Serum Protein (GSP), Lipoprotein (a) (Lp (a)), and Cystatin C assays.
Launch of glycated hemoglobin assay for diagnosing diabetes mellitus is expected to hamper the global glycated albumin assay market growth
Continuous research and development in assay technology has led to approvals and introduction of better and affordable products in the field of clinical diagnosis. For instance, in June 2019, Abbott received the U.S. FDA approval for its Afinion HbA1c Dx assay, a rapid point-of-care test for the diagnosis of diabetes. The test delivers accurate and precise1,2 glycated hemoglobin (HbA1c) results. The Afinion HbA1c Dx assay, used for monitoring and diagnosis, complements the Afinion HbA1c assay, which is used for monitoring only. However, launching of such advanced glycated hemoglobin assay is expected to hinder the glycated albumin assay market growth over the forecast period.
Global Glycated Albumin Assay Market- Regional Analysis
On the basis of region, the global glycated albumin assay market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in the market, owing to increasing prevalence of diabetes in North America. For instance, according to the U.S. Centers for Disease Control and Prevention (CDC), in 2017, over 100 million adults were diagnosed with diabetes and prediabetes. Furthermore, according to CDC, as of 2015, around 30.3 million adults (9.4% of total U.S. population) suffered from diabetes and another 84.1 million suffered from prediabetes.
Moreover, Europe glycated albumin assay market is expected to witness significant growth over the forecast period, owing to the availability of CE marked glycated albumin assay in Europe. For instance, the glycated albumin assay, Lucica Glycated Albumin-L, developed by Asahi Kasei Pharma is available in the Europe market. The company received CE marking for Lucica Glycated Albumin-L in 2015
Figure 2: Global Glycated Albumin Assay Market Share (%), By Region
Source: Coherent Market Insights Analysis (2019)
Global Glycated Albumin Assay Market - Competitive Landscape
Key players operating in the global glycated albumin assay market include Asahi Kasei Corporation, Diazyme Laboratories, Inc., LifeSpan BioSciences, Inc., Biomatik Corporation, Abbexa Ltd., Geno Technology, Inc., DRG International, Inc., AMS Biotechnology (Europe) Limited, Abnova Corporation, Ethos Biosciences, Inc., Epinex Diagnostics Inc., DxGen Corp., and PathShodh Healthcare Private Limited
Glycated albumin assay is used in the clinical management of diabetes, which measures and monitors the glycated serum proteins (glycated albumin). Glycated albumin assay is point-of-care test offering various advantages over the conventional diagnostic techniques for diagnosis of diabetes, and which makes it cost-effective and reliable over conventional assay techniques.
There are various laboratory tests such as glycated hemoglobin (A1C), fasting plasma glucose (FG), and two-hour plasma glucose (2hG) used to diagnose diabetes mellitus. Glycated hemoglobin (A1C) assay is another major laboratory reference test for glycemic monitoring in diagnosis of diabetes mellitus (DM). However, glycated hemoglobin (A1C) assay is not recommended in certain clinical conditions, as it influences hemoglobin metabolism. Increased hemoglobin metabolism results in high glycation of proteins in the body, which represents biochemical abnormality in the body. To overcome this issues, many research institutes and laboratories are adopting glycated albumin assay as laboratory test for diagnosing DM. Moreover, GA assay have gained significant traction in last decade due to its advantages and benefits over glycated hemoglobin assay.
Glycated assay dose not influenced by the concentration of other serum proteins, as it is specific to albumin glycation rates. Moreover, the test does not require fasting conditions to measure and reflects the short term glycemia, due to half life time of albumin. Unlike glycated hemoglobin assay, the presence of hemolytic processes and abnormal Hb in body the does not alter the functioning of GA assay. Furthermore, glycated albumin assay have proven to be more effective marker than glycated hemoglobin assay in conditions such as anemia, pregnancy, postprandial hyperglycemia, and DM
Thus, advantages of glycated albumin assay are expected to drive growth of the global glycated albumin assay market over the forecast period.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section